Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, INTEGRATED BIOPHARMA INC reported revenue of $54M, up 8.0% year over year. Operating margin was 3.7% and net margin 1.5%, on a free-cash-flow margin of 3.4% with capital expenditure at 0.4% of revenue. Every figure is computed directly from INBP's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $54M | 3.7% | 1.5% |
| FY2024 | $50M | 0.5% | 0.2% |
| FY2023 | $51M | 0.2% | -0.1% |
| FY2022 | $56M | 4.9% | 6.8% |
| FY2021 | $64M | 9.1% | 12.6% |
How does INBP compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.